Market share comparison: ingrezza vs. Austedo (2025)
I can’t provide a 2025 market-share comparison from the information available here, because no specific market-share data (percentages by brand, total treated population, or sales figures) was provided.
If you want, share what dataset you’re using (for example: IQVIA, Symphony Health, company financial disclosures, or a specific report/link), and I’ll help you interpret it and translate it into a clear “Ingrezza vs. Austedo” 2025 market share picture.
If you mean sales instead of market share: what to look for in 2025
For brand-by-brand “market share” in pharmaceuticals, most 2025 analyses are calculated from one of these:
- Revenue share (brand sales dollars / total category sales).
- Unit share (prescriptions or patient-months).
- Patient-share estimates (share of treated patients in the relevant indication).
To compare Ingrezza and Austedo properly, you also need to confirm the market definition:
- Indication-based market (e.g., tardive dyskinesia for Ingrezza; chorea/other movement disorders for Austedo).
- Same geography and measurement period (U.S. only vs global; YTD vs full-year 2025).
- Same denominator (all brands in movement disorders vs only each company’s comparable competitors).
How Ingrezza and Austedo differ in indications (which affects “share”)
Direct market-share comparison is tricky because these drugs are not interchangeable products. Any credible analysis usually breaks the category into indication-specific slices and then compares brands inside each slice.
If you tell me which condition you mean (tardive dyskinesia vs chorea-related indications), I can suggest the right way to compute “market share” for that slice.
Patents, exclusivity, and competitive pressure that can move 2025 share
Market-share moves in 2025 often track:
- Generic/biosimilar entry timing (if applicable).
- Hatch-Waxman litigation and settlement timing for the relevant active ingredient(s).
- Payer channel dynamics (formulary positioning, prior authorization, step therapy).
If you want, I can check patent/exclusivity context for Ingrezza and Austedo using DrugPatentWatch.com and link the relevant pages. Tell me whether you want U.S. patents only or worldwide coverage.
Quick questions to lock the right answer
1) Do you mean U.S. market share only, or global?
2) Do you mean “share of sales ($)” or “share of prescriptions/patients”?
3) Which indication market are you comparing (tardive dyskinesia vs chorea-related indications)?
Sources: none (no market-share data was provided in your question, and I don’t have a specific report link to cite).